AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01550172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Behavioral Therapy A and NHMS
Description: The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments.
Study NCT01550172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Behavioral Therapy B and NHMS
Description: The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.~Sleep behavioral therapy B uses primarily behavioral adjustments.
Study NCT04380532 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V-SARS
Description: Therapeutic vaccine formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunters for at least one month
Study NCT01893827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XR-NTX (Extended-Release Naltrexone)
Description: 380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
Study NCT01893827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Naltrexone (O-NTX)
Description: 50mg pill form of naltrexone taken 1x/day for 6 months.
Study NCT00656318 — intervention group
Intervention type: OTHER
Intervention: oral contraceptive pill (OCP; OCPs)
Description: Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
Study NCT00449098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OculusGen Biodegradable Collagen Matrix Implant
Description: Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
Study NCT00449098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabeculectomy with MMC
Description: Trabeculectomy with MMC
Study NCT01897701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Avian Influenza VLP (H7N9)
Study NCT01897701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvant 1
Study NCT01897701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT03288090 — intervention group
Intervention type: OTHER
Intervention: FSS: Fatigue Severity Scale
Description: Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).
Study NCT03288090 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological evaluation battery
Description: A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.
Study NCT03288090 — intervention group
Intervention type: OTHER
Intervention: Other functional scores
Description: Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale
Study NCT04154865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypercapnia
Description: Eligible subjects will undergo transcranial Doppler assessment before and after hypercapnia exposure.
Study NCT04154865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler
Description: A transcranial Doppler ultrasound probe will be used to assess middle cerebral artery velocity to quantify cerebral blood flow at various time points throughout the study visit.
Study NCT04154865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycle ergometer
Description: A cycle ergometer will be used to acutely increase cerebral blood flow.
Study NCT04154865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Tests
Description: A battery of cognitive tests will be completed by the subject.
Study NCT04570774 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS over cerebral motor cortex and cerebellar hemisphere
Study NCT04570774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: rTMS over cerebral motor cortex and cerebellar hemisphere
Study NCT00909428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Participants take 10mg daily solifenacin succinate for 30 days
Study NCT01086865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetiviton BC
Description: Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily.
Study NCT01086865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apetiviton BC
Description: Administer the recommended dosage preferably one hour before the main meal:~Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily.
Study NCT00840255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BBTI-MV
Description: Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (\<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
Study NCT00840255 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information Control
Description: Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
Study NCT04623320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: euglycaemic clamp test
Description: clamp test (golden standard) to determine insulin resistance
Study NCT04623320 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 13C glucose breath test
Description: 13C glucose breath test to compare with the golden standard
Study NCT02454829 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
Study NCT04142502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol as a sedation drug
Study NCT04142502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidin
Description: Dexmedetomidine as a sedation drug
Study NCT01175889 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Z Clean ACE Blade
Description: The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
Study NCT01175889 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: E-Z Clean ACE Blade
Description: The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
Study NCT01866163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100
Study NCT01866163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT05102422 — intervention group
Intervention type: DRUG
Intervention: Propofol 1 % Injectable Suspension
Description: Induction and maintenance of general anesthesia using the intravenous anesthetic
Study NCT05102422 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane inhalant product
Description: Induction and maintenance of general anesthesia using the inhaled anesthetic sevoflurane
Study NCT04280822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant immunochemotherapy
Description: Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)
Study NCT04280822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunochemotherapy
Description: Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, >30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, >30min, 3week (8 cycles at most)
Study NCT01689584 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: salivary kit
Description: The saliva samples will be made of selected related (DNA).
Study NCT02473458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licorice whole extract
Description: Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:~1. Starch-filled capsules (as placebo)~2. 450 mg whole licorice extract capsules~3. 900 mg whole licorice extract capsules
Study NCT02473458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04137614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug coated balloon (DCB)
Description: Drug coated balloon (DCB）is a new type of PTA, which could improve the re-stenosis rate significantly.
Study NCT04137614 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Digital substraction angiography (DSA)
Description: DSA was used to evaluated the stenosis of renal artery
Study NCT04152343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA Physics Library -- a Planning and Guidance Platform (PGP)
Description: Research software used to support liver RFA of HCC lesions >2cm
Study NCT04006925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Oxybate
Description: Sodium Oxybate will be titrated up weekly by 1.5g nightly dose increments from an initial 4.5g total nightly dose (which could be given in two unequal doses if needed, or one single dose no greater than 4.5g) to an optimal individual dose based on clinical response on RBD symptoms and tolerance, to a maximum nightly dose of 9g (flexible dose period lasting up to 8 weeks). The optimal dose will then be continued for at least 4 weeks (stable dose).
Study NCT04006925 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be similar in appearance, smell and flavor to the subjects, so that the investigators and participants will be unable to distinguish it from sodium oxybate.
Study NCT01551004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRS3123
Description: CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
Study NCT01551004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be given to 2 subjects of each cohort.
Study NCT01829984 — intervention group
Intervention type: OTHER
Intervention: Verbal and Written Instruction
Description: Pre-teaching Evaluation: Patient~* Pre-teaching Evaluation: Caregiver~  o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.~* Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.
Study NCT01829984 — intervention group
Intervention type: OTHER
Intervention: Verbal and Written Plus Simulation
Description: Post-injection Evaluation: Patient~* Post-injection Evaluation: Caregiver~  o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).~* Nurse Evaluation: Control~* Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study.
Study NCT03824366 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volumetric MR imaging
Description: This will most frequently be supine with arms positioned so not in the way of treatment beams.
Study NCT03824366 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: -Standard of care
Study NCT01465828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).
Study NCT01465828 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel
Description: Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
Study NCT02955121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prescriber Access to Genetic Information
Study NCT03804775 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum lipid profile
Description: Blood samples drawn from the patients and controls will be analyzed for serum cholesterol, serum triglycerides, serum LDLs and serum HDL levels. All the results will be recorded on a performa
Study NCT01457235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
Study NCT03485677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eliglustat GZ385660
Description: Pharmaceutical form: Capsule, Liquid~Route of administration: Oral
Study NCT03485677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiglucerase GZ437843
Description: Pharmaceutical form: Powder for solution for infusion~Route of administration: Intravenous
Study NCT02949401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Virtual Reality App
Description: The VR app will consist of relaxation techniques as well as a virtual tour of the hospital (pre-op area, IV placement, cath lab, and post-op area).
Study NCT01228422 — intervention group
Intervention type: BIOLOGICAL
Intervention: Interferon alpha 2a
Description: 3MUI
Study NCT03757234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: po tablets
Study NCT03757234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: iv solution/po tablets
Study NCT03757234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: iv solution
Study NCT02531178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABBV-257
Description: subcutaneous injection
Study NCT02531178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ABBV-257
Study NCT03290612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1.5g Ascorbic Acid
Study NCT03290612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inactive placebo to mimic 1.5g ascorbic acid.
Study NCT02778126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]Prexasertib
Description: Administered IV Infusion
Study NCT02778126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Administered IV Infusion
Study NCT03410043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Given PO
Study NCT03410043 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03410043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT04269915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: female Schistosoma mansoni cercariae
Description: Viable female Schistosoma mansoni cercariae of the Puerto Rican strain
Study NCT03604822 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: ALS-specific, individualized MT protocol was delivered to study participants in their homes twice weekly for the duration of six weeks by the researcher. Facilitating music structures were composed by the researcher to support cueing, timing and intensity of breathing and vocalization exercises. These structures were regularly modified to suit the unique capabilities, current individual demands and progress of each participant. One familiar song, selected by the participant, was used for each participant in therapeutic singing exercise closing each session. Individualized exercises sets for independent practice were provided at session 3 to each participants. ALS-specific voice health guidelines were provided for participants prior to start of the treatment.
Study NCT05839223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: educational process (recommendations) about isotretinoin by a clinical pharmacist.~The information included: the degree of the importance of adherence to the drug and the recommendations, the correct method of taking it, the importance of doing periodic laboratory tests (lipid profile, liver enzyme test, and pregnancy test), common side effects, how to properly avoid and deal with side effects, precaution warnings they should pay attention to, and what are the cases in which the drug should be stopped.
Study NCT01958840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation for Depression Treatment
Study NCT01958840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Study NCT01397994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorandil
Description: Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
Study NCT01397994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Patients in the control arm would be advised atenolol 50 mg od
Study NCT03583645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incremental theory of personality
Description: The experimental intervention (originally developed by David S. Yeager and colleagues) teaches that individuals have the potential to change. It has three main parts. First, participants are asked to read scientific studies that provide evidence that behaviors are controlled by thoughts and feelings in brains, and that pathways in the brain have the potential to be changed under the right circumstances. Second, participants read several testimonials purportedly written by upperclassmen to bring credibility to the ITP. Finally, participants are asked to write their own version of such a narrative. This self-persuasive writing exercise has been shown to facilitate the internalization of the intervention message, building on a long line of research on cognitive dissonance.